|July 31, 2014|
|11:29 EDT||LH, DGX, BRLI||FDA announces steps to ensure reliable diagnostic test results|
The FDA announced that it took "important steps to ensure that certain tests used by health care professionals to help diagnose and treat patients provide accurate, consistent and reliable results." The FDA issued a final guidance on the development, review and approval of companion diagnostics, which are tests used to identify patients who will benefit from or be harmed by treatment with a certain drug. Companion diagnostic tests are intended to aid physicians in selecting appropriate therapies for individual patients, the agency said. These tests are commonly used to detect certain types of gene-based cancers. The FDA also is notifying Congress of its intention to publish a proposed risk-based oversight framework for laboratory developed tests, which are designed, manufactured and used within a single laboratory. The agency also intends to publish a draft guidance outlining how laboratories can notify the FDA that they are currently manufacturing and using LDTs, how to provide information about their LDTs, and how they can comply with the medical device reporting requirements. Publicly traded laboratory companies include LabCorp (LH), Quest Diagnostics (DGX) and Bio-Reference Labs (BRLI). Reference Link
News For LH;DGX;BRLI From The Last 14 Days
|October 23, 2014|
|07:13 EDT||DGX||Quest Diagnostics narrows FY14 adjusted EPS view to $4.03-$4.07 from $4.00-$4.10|
Consensus for FY14 EPS is $4.05. Narrows FY14 revenue growth view to 3.5% from 2.5%-3.5%.
|07:12 EDT||DGX||Quest Diagnostics reports Q3 adjusted EPS $1.10, consensus $1.08|
Reports Q3 revenue $1.9B, consensus $1.87B.
|October 22, 2014|
|15:37 EDT||DGX||Notable companies reporting before tomorrow's open |
Notable companies reporting before tomorrow's market open, with earnings consensus, include Comcast (CMCSA), consensus 71c; Union Pacific (UNP), consensus $1.52; 3M (MMM), consensus $1.96; AbbVie (ABBV), consensus 77c; Celgene (CELG), consensus 95c; Eli Lilly (LLY), consensus 67c; Occidental Petroleum (OXY), consensus $1.57; Caterpillar (CAT), consensus $1.36; Alexion Pharmaceuticals (ALXN), consensus $1.16; Precision Castparts (PCP), consensus $3.32; Raytheon (RTN), consensus $1.60; American Electric Power (AEP), consensus $1.02; Southwest Airlines (LUV), consensus 53c; Lorillard (LO), consensus 90c; T. Rowe Price (TROW), consensus $1.15; Mead Johnson (MJN), consensus 91c; Zimmer Holdings (ZMH), consensus $1.30; Nucor (NUE), consensus 73c; Nielsen (NLSN), consensus 65c; Prologis (PLD), consensus 46c; Sigma-Aldrich (SIAL), consensus $1.06; Under Armour (UA), consensus 40c; EQT (EQT), consensus 56c; Dr Pepper Snapple (DPS), consensus 88c; Cameron International (CAM), consensus $1.10; Coca-Cola Enterprises (CCE), consensus 89c; Quest Diagnostics (DGX), consensus $1.08; CMS Energy (CMS), consensus 41c; Airgas (ARG), consensus $1.29; PulteGroup (PHM), consensus 36c; Diamond Offshore (DO), consensus 79c; Bemis (BMS), consensus 67c.
|October 20, 2014|
|08:45 EDT||LH||LabCorp launches HIV GenoSure Archive|
Laboratory Corporation of America Holdings and Monogram Biosciences, Inc., part of the LabCorp Specialty Testing Group, today announced the launch of HIV GenoSure Archive, the first laboratory test to help optimize antiretroviral drug regimens in virally suppressed HIV patients. GenoSure Archive was developed using the Next Generation Sequencing platform.
|October 16, 2014|
|15:10 EDT||DGX||American College of Gastroenterology to hold annual meeting|
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
|October 15, 2014|
|19:16 EDT||LH||LabCorp acquisition of LipoScience clears antitrust approval|
Laboratory Corporation of America Holdings, or LabCorp (LH), announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience, Inc. (LPDX) by LabCorp. The transaction is expected to close in Q4.
|16:11 EDT||LH||LabCorp's LipoScience acquisition clears antitrust approval |
LipoScience (LPDX) announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience by Laboratory Corporation of America Holdings (LH). The transaction remains subject to other customary closing conditions set forth in the Agreement and Plan of Merger, dated September 24. The transaction is expected to close in Q4.